AARP says bipartisan amendment may bring down medication costs Overview: The U.

The Senate rejected another amendment sponsored by Sen also. Lautenberg which could have created an unnecessary roadblock for prescription medication importation. In a move made to block importation, the amendment prohibited importation of prescription medications unless the Secretary of Health and Human Services can certify that it is safe to take action. Even though safety provisions are built in to the AARP-endorsed Dorgan-Snowe amendment already, this version is made to create administrative hurdles to avoid importation effectively. VOTED YES ON RX IMPORTATION VOTED NO ON RX IMPORTATION AMENDMENT TO LESSEN DRUG AMENDMENT TO LESSEN DRUG MARYLAND COSTS COSTS ——- – ————————– – ————————- – Cardin, Ben X ———- – — – Mikulski, Barbara X —————- – — – ** What sort of legislator votes on issues is only one element in evaluating his or her legislative performance, that ought to also include specific things like constituency solutions and committee work.The proprietary XEN45 technology facilitates aqueous fluid movement to lower IOP while protecting against the prospect of hypotony that’s associated with current subconjunctival methods. ‘The acquisition of AqueSys and XEN45 is certainly highly complementary to our leadership position in eye treatment and underscores our commitment to build up and commercialize treatments that advance treatment and add worth for ophthalmologists and their individuals,’ said Brent Saunders, CEO and President of Allergan. ‘The treating glaucoma is increasingly shifting to dropless therapies given the challenges of patient compliance. The XEN45 device provides a minimally invasive method of lowering IOP for doctors and their individuals seeking new ways to treat glaucoma that go beyond conventional eye drop remedies.’ Related StoriesQ BioMed indications definitive license contract with Mannin ResearchAllergan enters into contract to acquire Aquesys and its own XEN45 programQuethera receives seed expenditure funding to develop gene therapy for glaucomaXEN45 provides received a CE mark in europe where it really is indicated for the reduction of intraocular pressure in sufferers with primary open angle glaucoma where previous medical treatments possess failed.